Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 11, 2026
Tango Therapeutics, Inc. (TNGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $55.3 million. Free cash flow was -$38.9 million. As of Jun 30, 2026 it held $1.0 billion in cash and investments and $32.0 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-55.34M
-42.4% vs year-ago quarter
Operating cash flow
$-38.87M
-6.4% vs year-ago quarter
Free cash flow
$-38.89M
-4.7% vs year-ago quarter
EPS
$-0.37
-5.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
168.61M
+51.5% vs year-ago quarter
Net cash
$982.00M
Q2 FY2026
Operating margin
-253.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1819133
- Former names
- BCTG Acquisition Corp. (until Aug 9, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $53.8M | $3.2M |
| Operating income | -$59.8M | -$48.8M | -$41.9M | $14.1M | -$41.0M |
| Net income | -$55.3M | -$45.5M | -$38.7M | $15.9M | -$38.9M |
| Diluted EPS | -$0.37 | -$0.32 | -$0.29 | $0.13 | -$0.35 |
| Operating cash flow | -$38.9M | -$44.4M | -$29.7M | -$31.0M | -$36.5M |
| Free cash flow | -$38.9M | -$44.4M | -$29.9M | -$31.1M | -$37.1M |
| Total assets | $1.1B | $435.8M | $398.7M | $210.1M | $237.9M |
| Total liabilities | $49.3M | $44.3M | $52.5M | $50.1M | $102.9M |
| Stockholders' equity | $1.0B | $391.5M | $346.2M | $160.0M | $135.0M |
| Cash and investments | $1.0B | $379.8M | $343.1M | $152.8M | $180.8M |
| Total debt | $32.0M | $32.8M | $33.6M | $34.8M | $35.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Aug 7, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 6, 2026 | Jul 31, 2026 |
All 424 Tango Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.